No Data
No Data
Femasys Expands Global Patent Portfolio To Support Innovative Women's Health Solutions
Express News | Femasys Inc: Expects Resulting Patent, When Issued, Will Have an Anticipated Expiration in 2044 at Earliest
Express News | Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of Femaseed® for Female Infertility Treatment
Femasys Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed for Female Infertility Treatment
Fluctuations are expected to continue in the early days of Trump's presidency, with Citigroup favoring Medical, Financial, and other defensive Industries.
In the market volatility and uncertainty following Trump's inauguration, defensive industries such as Medical Care and finance are favored in the model portfolio created by Citigroup strategists.
Femasys's Strategic Partnerships and Market Expansion Drive Buy Rating